alt

ALT-100 (HumanIgG4) is a human-derived antibody expressed in CHO cells, targeting NAMPT. It consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For inflammation or fibrotic diseases, the isotype control for ALT-100 (HumanIgG4) is HumanIgG4(S228P) kappa, Isotype Control. For other indications, refer to HumanIgG1kappa, Isotype Control for the isotype control of ALT-100.

Inbakicept is a dimer of IL-15 receptor alpha sushi domain and immunoglobulin G1 (human Fc fragment) fusion protein, which is an IL-15 super agonist protein complex. Inbakicept binds to IL-15 antibody Nogapendekin alfa to form the complex Nogapendekin alfa inbakicept (ALT-803) in a 1:2 ratio. ALT-803 has potential anticancer and anti-tumor activities, which can be used to study breast cancer.

Oregovomab (Alt-2 monoclonal antibody), a murine mAb, specifically targets CA125, inducing a cytotoxic immune response against tumor cells that express CA125 [1] [2].

Berahyaluronidase alfa (ALT-B4) is a modified hyaluronidase enzyme. It is a fusion protein targeting Hyaluronidase PH-20, Sperm surface protein PH-20, HYAL3, Sperm adhesion molecule 1, PH20, SPAM1, Hyal-PH20, and Hyaluronoglucosaminidase PH-20. Berahyaluronidase alfa is utilized in research concerning advanced and metastatic solid tumors. Recommended isotype control: 3-305-Hyaluronidase PH-20 (human) fusion protein with 303-322-hyaluronidase HYAL-1 (human) fusion protein with 327-433-hyaluronidase PH-20 (human).

ALT-836 (TNX-832) is a humanized antibody expressed in CHO cells that targets F3/Factor III/Tissue Factor/CD142. It features a huIgG4SP type heavy chain and a huk type light chain, with a predicted molecular weight (MW) of 150 kDa. Refer to HumanIgG4kappa, Isotype Control for its isotype control.

ALT-100 (HumanIgG1) is a human-derived IgG1 monoclonal antibody that targets NAMPT. For its isotype control, please refer to HumanIgG1kappa, Isotype Control.

Zaltenibart is a chimeric humanized antibody of the IgG4κ type, specifically targeting MASP3. The corresponding isotype control for this antibody is: HumanIgG4(S228P) kappa, Isotype Control.

Ruzaltatug is a humanized IgG1 antibody targeting ERBB3.

Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host disease (GVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.

Lixudebart is a humanised monoclonal antibody targeting CLDN1 (Claudin-1), which can be used to reverse organ fibrosis (such as pulmonary fibrosis) and reduce initial ALT/AST levels.